Real-world treatment patterns and outcomes in patients initiating lurasidone for the treatment of schizophrenia in Europe
Introduction Lurasidone is a second-generation antipsychotic shown to have a lower risk of weight gain and a lower incidence of metabolic adverse events compared with some medications in the same class. Objectives To describe treatment patterns, clinical outcomes and adverse drug reactions (ADRs)...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2022-06-01
|
| Series: | European Psychiatry |
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S0924933822005375/type/journal_article |
| _version_ | 1827754781321461760 |
|---|---|
| author | A. Jones M. Sargeant M. Andiappan |
| author_facet | A. Jones M. Sargeant M. Andiappan |
| author_sort | A. Jones |
| collection | DOAJ |
| description |
Introduction
Lurasidone is a second-generation antipsychotic shown to have a lower risk of weight gain and a lower incidence of metabolic adverse events compared with some medications in the same class.
Objectives
To describe treatment patterns, clinical outcomes and adverse drug reactions (ADRs) over 12 months following lurasidone initiation in patients with schizophrenia.
Methods
This was a multi-centre observational study involving data collection from patients’ medical records, conducted in seven mental health centres in the United Kingdom (UK) and Switzerland. The study included patients aged ≥18 years who initiated lurasidone after 1 January 2016 for the treatment of schizophrenia. Data were collected from medical records both retrospectively and prospectively using a standardised data collection form. Data collected included patient characteristics, treatment history, lurasidone regimens, clinical outcomes and ADRs.
Results
Forty-eight patients participated in the study. The median (interquartile range [IQR]) age at lurasidone initiation was 33.5 (25.5-50.3) years and 31 (65%) patients were male. The median (range) lurasidone starting dose was 37 mg daily (9.3–148 mg). Thirty-eight (79%) patients continued lurasidone for the entire 12-month follow-up period. Among the 14 (29%) patients with documented relapse, the median (IQR) time to relapse was 3.4 (1.5–7.9) months. Five ADRs were recorded in patient notes judged as related to lurasidone: agitation, nausea, akathisia, somnolence and vomiting (one patient each).
Conclusions
In this real-world study of patients with schizophrenia in the UK and Switzerland, 79% of patients continued lurasidone for at least 12 months, and ADRs were reported rarely in patient notes.
Disclosure
This study was sponsored by CNX Therapeutics Ltd (formerly Sunovion Pharmaceuticals Europe Ltd). AJ is an employee of CNX Therapeutics. MA is an employee of OPEN HEALTH who was contracted by CNX Therapeutics for data analysis and medical writing.
|
| first_indexed | 2024-03-11T07:54:16Z |
| format | Article |
| id | doaj.art-24bd1d7b70db43339b0b8936a8afac70 |
| institution | Directory Open Access Journal |
| issn | 0924-9338 1778-3585 |
| language | English |
| last_indexed | 2024-03-11T07:54:16Z |
| publishDate | 2022-06-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | European Psychiatry |
| spelling | doaj.art-24bd1d7b70db43339b0b8936a8afac702023-11-17T05:05:57ZengCambridge University PressEuropean Psychiatry0924-93381778-35852022-06-0165S205S20510.1192/j.eurpsy.2022.537Real-world treatment patterns and outcomes in patients initiating lurasidone for the treatment of schizophrenia in EuropeA. Jones0M. Sargeant1M. Andiappan2CNX Therapeutics, Psychiatry, London, United KingdomHywel Dda University Health Board, St David’s Hospital, Wales, United KingdomOPEN Health, Evidence And Access, Marlow, United Kingdom Introduction Lurasidone is a second-generation antipsychotic shown to have a lower risk of weight gain and a lower incidence of metabolic adverse events compared with some medications in the same class. Objectives To describe treatment patterns, clinical outcomes and adverse drug reactions (ADRs) over 12 months following lurasidone initiation in patients with schizophrenia. Methods This was a multi-centre observational study involving data collection from patients’ medical records, conducted in seven mental health centres in the United Kingdom (UK) and Switzerland. The study included patients aged ≥18 years who initiated lurasidone after 1 January 2016 for the treatment of schizophrenia. Data were collected from medical records both retrospectively and prospectively using a standardised data collection form. Data collected included patient characteristics, treatment history, lurasidone regimens, clinical outcomes and ADRs. Results Forty-eight patients participated in the study. The median (interquartile range [IQR]) age at lurasidone initiation was 33.5 (25.5-50.3) years and 31 (65%) patients were male. The median (range) lurasidone starting dose was 37 mg daily (9.3–148 mg). Thirty-eight (79%) patients continued lurasidone for the entire 12-month follow-up period. Among the 14 (29%) patients with documented relapse, the median (IQR) time to relapse was 3.4 (1.5–7.9) months. Five ADRs were recorded in patient notes judged as related to lurasidone: agitation, nausea, akathisia, somnolence and vomiting (one patient each). Conclusions In this real-world study of patients with schizophrenia in the UK and Switzerland, 79% of patients continued lurasidone for at least 12 months, and ADRs were reported rarely in patient notes. Disclosure This study was sponsored by CNX Therapeutics Ltd (formerly Sunovion Pharmaceuticals Europe Ltd). AJ is an employee of CNX Therapeutics. MA is an employee of OPEN HEALTH who was contracted by CNX Therapeutics for data analysis and medical writing. https://www.cambridge.org/core/product/identifier/S0924933822005375/type/journal_articleschizophréniaAntipsychoticslurasidoneobservational |
| spellingShingle | A. Jones M. Sargeant M. Andiappan Real-world treatment patterns and outcomes in patients initiating lurasidone for the treatment of schizophrenia in Europe European Psychiatry schizophrénia Antipsychotics lurasidone observational |
| title | Real-world treatment patterns and outcomes in patients initiating lurasidone for the treatment of schizophrenia in Europe |
| title_full | Real-world treatment patterns and outcomes in patients initiating lurasidone for the treatment of schizophrenia in Europe |
| title_fullStr | Real-world treatment patterns and outcomes in patients initiating lurasidone for the treatment of schizophrenia in Europe |
| title_full_unstemmed | Real-world treatment patterns and outcomes in patients initiating lurasidone for the treatment of schizophrenia in Europe |
| title_short | Real-world treatment patterns and outcomes in patients initiating lurasidone for the treatment of schizophrenia in Europe |
| title_sort | real world treatment patterns and outcomes in patients initiating lurasidone for the treatment of schizophrenia in europe |
| topic | schizophrénia Antipsychotics lurasidone observational |
| url | https://www.cambridge.org/core/product/identifier/S0924933822005375/type/journal_article |
| work_keys_str_mv | AT ajones realworldtreatmentpatternsandoutcomesinpatientsinitiatinglurasidoneforthetreatmentofschizophreniaineurope AT msargeant realworldtreatmentpatternsandoutcomesinpatientsinitiatinglurasidoneforthetreatmentofschizophreniaineurope AT mandiappan realworldtreatmentpatternsandoutcomesinpatientsinitiatinglurasidoneforthetreatmentofschizophreniaineurope |